SYNCOM
FORMULATIONS (INDIA) LIMITED
A WHO-GMP & ISO 9001:2015 Certified Company
CIN No.: L24239MH1988PLC047759
Regd. Off. : 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (East), Mumbai - 400 093, INDIA, Tel.: +91-22-42824400, Email: sfil87@sfil.in
Corp. Off. : 207, Saket Nagar, Indore - 452 018, INDIA. Tel. : +91-731-2560458 / 2700458, Email : info@sfil.in, Website : www.sfil.in
Works : 256-257, Sector-I, Pithampur, Dist.-Dhar, M.P. - 454 775, INDIA, Tel.: +91-7292-403122 / 407039, Email : info@sfil.in

SYNCOM/SE/2026-27 **13th November, 2026**

Online filing at: www.listing.bseindia.com and
https://neaps.nseindia.com/NEWLISTINGCORP/login.jsp

To,
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai (M.H.) 400 001
BSE CODE:524470

To,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai- 400051
NSE SYMBOL: SYNCOMF

Subject: Submission of Standalone & Consolidated Unaudited Financial Results along with Limited Review Report, Statement of Assets and Liabilities and Cash Flow Statements for the Quarter and Half year ended on 30th September, 2026, pursuant to Regulation 33(3) of the SEBI (LODR) Regulations, 2015.

Dear Sir/Ma'am,
This is in continuation of our letter bearing reference no. **SYNCOM/SE/2026-27** dated 4th November, 2026, regarding intimation of the Board meeting scheduled to be held for consideration and approval of Standalone and Consolidated Un-Audited Financial Results of the Company for the Quarter/ Half Year ended 30th September, 2026.

Pursuant to Regulation 33(3) of SEBI (LODR) Regulations, 2015, we are pleased to submit herewith the following:

1. Standalone and Consolidated Un-Audited Financial Results of the Company for the Quarter/ Half Year ended on 30th September, 2026;
2. Standalone and Consolidated Limited Review Report by the Statutory Auditors of the company for the Quarter/ Half Year ended on 30th September, 2026;
3. Standalone and Consolidated Un-Audited Statement of Assets and Liabilities for the Half Year ended on 30th September, 2026; and
4. Standalone and Consolidated Un-Audited Statement of Cash Flow for the Half year ended on 30th September, 2026.

The aforesaid financial results were duly **considered and approved by the Board of Directors** at its meeting held on **Friday, 13th November, 2026**, which **commenced at 3:00 P.M. and concluded at 4:30 P.M.**
We further wish to inform you that Company is in the process of filing the aforesaid financial results in XBRL format within the stipulated time and the same shall also be hosted on the website of the company in due course.
Further, the Financial Results will be published in widely circulated English and Marathi (Vernacular) newspaper in the prescribed format within the stipulated time period.
You are requested to kindly take the aforesaid unaudited Financial Results, Statement of Assets and Liabilities and Cash Flow along with Limited Review Report, on record for your reference and record.
Thanking you,

Thanking You,
Yours Faithfully,
For, SYNCOM FORMULATIONS (INDIA) LIMITED

Vaishali Agrawal
Digitally signed by Vaishali Agrawal
Date: 2026.11.13 16:38:54 +05'30'

CS VAISHALI AGRAWAL
COMPANY SECRETARY &
COMPLIANCE OFFICER
Encl: a/a

SANJAY MEHTA & ASSOCIATES
Chartered Accountants

338, Saket Nagar, Indore - 452 018 (M.P.)
Phone : 0731-2563625, 4274391, 94250 62964
E-mail : office@smaonline.in

Limited Review Report on Un-audited Standalone Financial Results for the Quarter & Half Year ended 30th September 2026 pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015

To,
The Board of Directors
SYNCOM FORMULATIONS (INDIA) LIMITED
Indore (M.P.)

We have reviewed the accompanying statement of Standalone Unaudited Financial Results of **SYNCOM FORMULATIONS (INDIA) LIMITED ("the Company"),** for the period ended September 30, 2026 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended including relevant circular issued by the SEBI from time to time.

This statement which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 Interim Financial Reporting" ("IND AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other Accounting principles generally accepted in India and in compliance with the Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended, including relevant circulars issued by the SEBI from time to time. Our responsibility is to issue a report on these Financial Statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "*Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued* by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015,including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, Sanjay Mehta &Associates
Chartered Accountants
FRN: 011524C

SANJAY MEHTA & ASSOCIATES INDORE

CA Manish Mittal
(Partner)
M. No. 079452
UDIN: 26079452ETSVMI2389

Place: Indore
Date: 13th November 2026

SYNCOM FORMULATIONS (INDIA) LIMITED

Regd.Off :- 7,Niraj Industrial Estate,Off Mahakali Caves Road,Andheri (E) Mumbai-400093
Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775
E Mail:- finance@sfil.in, Website:- www.sfil.in, CIN :- L24239MH1988PLC047759

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTERLY AND HALF YEARLY ENDED 30TH SEPTEMBER, 2026

Rs. In Lakhs except EPS

S. No.	Particulars	Quarter Ended			Year to date Ended		Year Ended
		30/09/2026	30/06/2026	30/09/2025	30/09/2026	30/09/2025	31/03/2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from Operations	13665.72	12465.95	12143.51	26131.67	23798.20	48657.28
2	Other Income	604.42	781.80	523.44	1386.22	1125.41	3096.63
3	**Total Income (1 + 2)**	**14270.14**	**13247.75**	**12666.95**	**27517.89**	**24923.61**	**51753.91**
4	EXPENSES						
	(a) Cost of materials consumed	4597.44	5877.61	4642.63	10475.05	10603.93	22093.67
	(b) Purchases of Stock-in-Trade	1545.04	1733.09	1535.33	3278.13	3097.26	6670.04
	(c) Changes in inventories of finished goods, Stock-in- Trade and work-in-progress	951.98	(1036.11)	909.36	(84.13)	292.97	(390.11)
	(d) Employee benefits expense	1693.24	1716.67	1673.08	3409.91	3268.52	6708.51
	(e) Finance costs	39.37	23.04	25.03	62.41	48.77	110.48
	(f) Depreciation and amortization expense	156.41	154.03	135.00	310.44	269.00	653.23
	(g) Other expenses	1852.36	1588.54	1510.77	3440.90	3085.71	5859.27
	Total expenses (4)	**10835.84**	**10056.87**	**10431.20**	**20892.71**	**20666.16**	**41705.09**
5	**Profit/(loss) before exceptional items and tax (3- 4)**	**3434.30**	**3190.88**	**2235.75**	**6625.18**	**4257.45**	**10048.82**
6	Exceptional Items	0.00	0.00	0.00	0.00	4.13	3.69
7	**Profit/(loss) before tax (5 - 6)**	**3434.30**	**3190.88**	**2235.75**	**6625.18**	**4261.58**	**10052.51**
8	Tax expense:						
	(1) Current tax	868.72	719.07	522.00	1587.79	953.60	2270.29
	(2) Deferred tax	26.03	12.89	29.64	38.92	50.94	181.42
9	**Profit (Loss) for the period from continuing operations (7-8)**	**2539.55**	**2458.92**	**1684.11**	**4998.47**	**3257.04**	**7600.80**
10	Profit/(loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
11	Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
12	Profit/(loss) from Discontinued operations (after tax) (10-11)	0.00	0.00	0.00	0.00	0.00	0.00
13	**Profit/(loss) for the period (9 + 12)**	**2539.55**	**2458.92**	**1684.11**	**4998.47**	**3257.04**	**7600.80**
14	Other Comprehensive Income						
	A(*i*) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	(*ii*) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	B (*i*) Items that will be reclassified to profit or loss	(46.95)	381.87	(5.58)	334.92	398.26	(360.73)
	(*ii*) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
15	**Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the period)**	**2492.60**	**2840.79**	**1678.53**	**5333.39**	**3655.30**	**7240.07**
16	Paid up Share Capital of the Company (Face Value 1/-)	9400.00	9400.00	9400.00	9400.00	9400.00	9400.00
17	Reserves excluding revaluation reserves	0.00	0.00	-	0.00	-	31830.45
18	Earnings per equity share (for continuing operation):						
	(1) Basic	0.27	0.26	0.18	0.53	0.35	0.81
	(2) Diluted	0.27	0.26	0.18	0.53	0.35	0.81
19	Earnings per equity share (for discontinued operation):						
	(1) Basic	0.00	0.00	0.00	0.00	0.00	0.00
	(2) Diluted	0.00	0.00	0.00	0.00	0.00	0.00
20	Earnings per equity share (for discontinued & continuing operations)						
	(1) Basic	0.27	0.26	0.18	0.53	0.35	0.81
	(2) Diluted	0.27	0.26	0.18	0.53	0.35	0.81

Place: Indore
Date: 13/11/2026

For, Syncom Formulations (India) Limited

Ankit Kedarmal Bankda
Chairman & Wholetime Director
Din : 02359461

SYNCOM FORMULATIONS (INDIA) LIMITED

Regd.Off :- 7,Niraj Industrial Estate,Off Mahakali Caves Road,Andheri (E) Mumbai-400093
Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775
E Mail:- finance@sfil.in, Website:- www.sfil.in, CIN :- L24239MH1988PLC047759

STANDALONE STATEMENT OF SEGMENT WISE REVENUE, RESULTS ALONG WITH QUARTERLY AND HALF YEARLY UNAUDITED RESULTS

S. No.	Particulars	Quarter Ended			Year to date Ended		Year Ended
		30/09/2026	30/06/2026	30/09/2025	30/09/2026	30/09/2025	31/03/2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	**Segment Revenue**						
	a) Pharmaceuticals Drugs & Formulations	14,127.27	13,135.78	12,567.69	27,263.05	24,630.21	51,274.35
	b) Trading of Commodities	14.44	27.84	-	42.28	104.56	110.03
	c) Renting of Property	128.43	84.13	99.26	212.56	188.84	369.53
	Total Segment Revenue	**14,270.14**	**13,247.75**	**12,666.95**	**27,517.89**	**24,923.61**	**51,753.91**
	Less: Inter Segment Revenue	-	-	-	-	-	-
	Total Income	**14,270.14**	**13,247.75**	**12,666.95**	**27,517.89**	**24,923.61**	**51,753.91**
2	**Segment Results Profit(+)/Loss(-) before tax and interest from each segment**						
	a) Pharmaceuticals Drugs & Formulations	3,346.89	3,134.50	2,167.52	6,481.40	4,128.04	9,865.61
	b) Trading of Commodities	7.49	1.99	(0.00)	9.48	1.35	(2.63)
	c) Renting of Property	119.28	77.43	93.26	196.71	176.83	300.01
	Total Profit before tax and Interest	**3,473.66**	**3,213.92**	**2,260.78**	**6,687.59**	**4,306.22**	**10,162.99**
	Less: i) Interest	39.37	23.04	25.03	62.41	48.77	110.48
	ii) Other Un-allocable Expenditure	-	-	-	-	-	-
	Profit before tax	**3,434.30**	**3,190.88**	**2,235.75**	**6,625.18**	**4,257.45**	**10,052.51**
3	**(Segment Asset-Segment Liabilities)**						
	Segment Asset						
	a) Pharmaceuticals Drugs & Formulations	47,333.36	45,500.08	40,128.78	47,333.36	40,128.78	43,517.55
	b) Trading of Commodities	0.29	4.56	251.35	0.29	251.35	66.51
	c) Renting of Property	9,254.62	9,257.24	4,733.44	9,254.62	4,733.44	9,342.00
	Total Segment Asset	**56,588.27**	**54,761.88**	**45,113.57**	**56,588.27**	**45,113.57**	**52,926.06**
	Un-allocable Assets	-	-	-	-	-	-
	Net Segment Asset	**56,588.27**	**54,761.88**	**45,113.57**	**56,588.27**	**45,113.57**	**52,926.06**
	Segment Liabilities						
	a) Pharmaceuticals Drugs & Formulations	9,737.28	10,563.27	7,332.38	9,737.28	7,332.38	11,523.42
	b) Trading of Commodities	3.09	12.50	2.11	3.09	2.11	4.12
	c) Renting of Property	284.07	284.17	133.40	284.07	133.40	168.07
	Total Segment Liabilities	**10,024.43**	**10,859.94**	**7,467.89**	**10,024.43**	**7,467.89**	**11,695.61**
	Un-allocable Liabilities	-	-	-	-	-	-
	Net Segment Liabilities	**10,024.43**	**10,859.94**	**7,467.89**	**10,024.43**	**7,467.89**	**11,695.61**

Notes:-

1. The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 13/11/2026
2. These above results have been prepared in compliance with the Indian Accounting Standard (referred to as "Ind AS") as notified prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules 2015 as amended from time to time.
3. The company is operating in 3 segments i.e. (a) Pharmaceuticals Drugs & Formulations (b) Trading of Commodities (c) Renting of Property, particulars of segment wise results are given as required.
4. As required under Regulation 33 of SEBI (LODR) Regulations, 2015 the limited review by the Statutory Auditors have been completed for the quarter and half year ended on 30th September 2026. The report does not have any impact on the above results and notes which needs explanation.
5. Previous period figures have been regrouped/reclassified wherever necessary to confirm to this period classification.
6. The Standalone Statement of Assets and Liabilities as at 30th September, 2026 and the Standalone Statement of Cash Flow is provided as an annexure to this statement.
7. During the current period, the Company has corrected its method of calculating Earnings Per Share (EPS). In previous years/Quarters, EPS was calculated considering Total Comprehensive Income. To comply with the requirements of Ind AS 33, the EPS has now been computed using Profit After Tax attributable to equity shareholders. Consequently, the comparative EPS for all preceding periods has been restated. There is no restatement in any line items only EPS is restated. The Figurs as Previouly reported and restated are as below

Previously Reported EPS (TCI)	Quarter Ended			Year Ended		Year Ended
	30/09/2026	30/06/2026	30/09/2025	30/09/2026	30/09/2025	31/03/2026
	Audited	Unaudited	Audited	Audited	Audited	Audited
Earnings per equity share (for discontinued & continuing operations)						
(1) Basic	NA	NA	0.18	NA	0.39	NA
(2) Diluted	NA	NA	0.18	NA	0.39	NA
Restated EPS (PAT))						
Earnings per equity share (for discontinued & continuing operations)						
(1) Basic	0.27	0.26	0.18	0.53	0.35	0.81
(2) Diluted	0.27	0.26	0.18	0.53	0.35	0.81

Place: Indore
Date: 13/11/2026

For, Syncom Formulations (India) Limited

Ankit Kedarmal Bankda
Chairman & Wholetime Director
Din : 02359461

SYNCOM FORMULATIONS (INDIA) LIMITED

Regd.Off :- 7,Niraj Industrial Estate,Off Mahakali Caves Road,Andheri (E) Mumbai-400093
Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775
E Mail:- finance@sfil.in, Website:- www.sfil.in, CIN :- L24239MH1988PLC047759

Standalone Statement of Assets & Liabilities as at 30/09/2026

Particulars Rs. In Lacs	30/09/2026 unaudited	31/03/2026 Audited
ASSETS		
Non-current assets		
(a) Property, Plant and Equipment	8,871.88	8,976.66
(b) Capital Work in Progress	361.77	-
(c) Intangible assets	38.08	39.72
(d) Investment Property	9,253.92	9,334.67
(e) Financial Assets		
(i) Investments	262.58	256.44
(ii) Fixed Deposits & Accrued Interest	1,557.41	1,541.45
(iii) Deposits	75.75	70.90
(f) Other Non Current Assets	763.19	102.84
Current assets		
(a) Inventories	4,240.78	6,284.75
(b) Financial Assets	-	
(i) Investments	17,098.01	10,651.64
(ii) Trade Receivables	11,722.41	10,760.31
(iii) Cash And Cash Equivalents	29.76	512.03
(iv) Bank Balances other than (iii) above	-	-
(v) Deposits	396.74	381.48
(vi) Loans & Advances	874.69	703.92
(d) Other Current Assets	1,041.30	3,309.25
Total	**56,588.27**	**52,926.06**
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share Capital	9,400.00	9,400.00
(b) Other Equity	37,163.84	31,830.45
Liabilities		
Non Current Liabilities		
(a) Financial Liabilities		
(i) Trade and other Deposits	275.04	157.65
(b) Provisions	481.32	541.17
(c) Deferred Tax Liabilities (Net)	851.39	812.47
(d) Other Non Current Liabilities	1.91	1.82
Current liabilities		
(a) Financial liabilities		
(i) Borrowings	1,552.36	68.13
(ii) Trade Payables	-	
Total Outstanding Dues of Micro Enterprises and Small Enterprises	620.49	585.22
Total Outstanding Dues of Creditors other than Micro Enterprises and Small Enterprises	3,823.24	6,843.68
(iii) Other Financial Liabilities	213.68	215.48
(b) Other Current Liabilities	1,047.70	1,846.93
(c) Provisions	1,157.31	623.06
Total	**56,588.27**	**52,926.06**

Place: Indore
Date: 13/11/2026

For, Syncom Formulations (India) Limited

Ankit Kedarmal Bankda
Chairman & Wholetime Director
Din : 02359461

SYNCOM FORMULATIONS (INDIA) LIMITED

Regd.Off :- 7,Niraj Industrial Estate,Off Mahakali Caves Road,Andheri (E) Mumbai-400093

Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775

E Mail:- finance@sfil.in, Website:- www.sfil.in, CIN :- L24239MH1988PLC047759

Standalone Cash Flow Statement for the year ended 30/09/2026

Particulars Rs. In Lacs	30/09/2026 Un-audited	31/03/2026 Audited
Cash Flow from Operating Activities		
Profit before extraordinary item and tax	6,625.18	10,048.82
Adjustments for:		
Gain on Sale of Machinery / (Loss on Sale of Vehicle)	-	3.69
Gain/(Loss) on Actuarial valuation of employee benefits	(8.51)	9.83
Depreciation	310.44	653.23
Depreciation Written Back	-	(745.29)
Finance Costs	62.41	110.48
Other Income	(1,374.23)	(3,020.36)
Operating Profit before working capital changes	**5,615.28**	**7,060.40**
Changes in Working Capital		
Inventory	2,043.97	(2,155.46)
Trade Receivables	(962.10)	(65.88)
Loans & Advances	(170.77)	(164.63)
Other Current Assets	2,252.69	(1,298.41)
Trade Payables	(2,985.17)	3,023.28
Other Financial Liabilities	(1.71)	4.30
Other Current Liabilities	(799.23)	1,484.68
Short Term Provisions	534.25	211.21
Changes in Working Capital	(88.07)	1,039.09
	-	
Cash Generated from Operations before Tax	5,527.21	8,099.49
Less: Income Tax Paid	1,587.79	2,270.29
Net Cash From Operating Activities	**3,939.42**	**5,829.20**
Cash Flow from Investing Activities		
Change in Property Plant and Equipment, Intangible Assets and Capital Work in Progress	(565.79)	(1,166.99)
Change in Investment Property	80.75	(4,601.23)
Change in Fixed Deposit & Accrued Interest	(15.96)	(322.78)
Change in Deposits	(4.85)	(4.28)
Change in Other Non Current Assets	(660.35)	(21.26)
Change in Trade & Other Deposits	117.39	24.30
Other Income	1,374.23	3,020.36
Change in Investment	(6,109.08)	(1,992.18)
Net Cash from Investing Activities	**(5,783.66)**	**(5,064.06)**
Cash Flow from Financing Activities		
Finance Costs	(62.41)	(110.48)
Change in Long Term Liabilities	(59.85)	124.33
Issue of Warrants & Share capital	-	-
Dividend Paid	-	
Borrowings	1,484.23	(336.19)
	-	
Net Cash from Financing Activities	**1,361.97**	**(322.34)**
Net Decrease in Cash & Cash Equivalents	(482.27)	**442.80**
Cash & Cash Equivalents at the beginning of the Period	512.03	69.23
Cash & Cash Equivalents at the End of Period	**29.76**	**512.03**

Place: Indore
Date: 13/11/2026

For, Syncom Formulations (India) Limited

Ankit Kedarmal Bankda
Chairman & Wholetime Director
Din : 02359461

SANJAY MEHTA & ASSOCIATES
Chartered Accountants

338, Saket Nagar, Indore - 452 018 (M.P.)
Phone : 0731-2563625, 4274391, 94250 62964
E-mail : office@smaonline.in

Limited Review Report on Un-audited Consolidated Financial Results for the Quarter and half year ended 30th September 2026 pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015

To,
The Board of Directors
SYNCOM FORMULATIONS (INDIA) LIMITED
Indore (M.P.)

1. We have reviewed the accompanying statement of Consolidated Unaudited Financial Results of **SYNCOM FORMULATIONS (INDIA) LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the period ended September 30, 2026 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended including relevant circular issued by the SEBI from time to time.

2. This statement which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 Interim Financial Reporting" ("IND AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other Accounting principles generally accepted in India and in compliance with the Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended, including relevant circulars issued by the SEBI from time to time. Our responsibility is to issue a report on these Financial Statements based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, *"Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued* by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. The Statement includes the results of the following entity:

S. No.	Name of the Company	Relationship with the Holding Company
1.	Sante Biotech Pvt. Ltd.	Wholly Owned Subsidiary
2.	Synmex Pharma Pvt. Ltd.	Wholly Owned Subsidiary
3.	Vincit Biotech International Pvt. Ltd.	Wholly Owned Subsidiary

SANJAY MEHTA & ASSOCIATES INDORE

5. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015,including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, Sanjay Mehta &Associates
Chartered Accountants
FRN: 011524C

SANJAY MEHTA & ASSOCIATES INDORE

Place: Indore
Date: 13th November 2026

CA Manish Mittal
(Partner)
M. No. 079452
UDIN: 26079452EIAFLU2593

SYNCOM FORMULATIONS (INDIA) LIMITED

Regd.Off :- 7,Niraj Industrial Estate,Off Mahakali Caves Road,Andheri (E) Mumbai-400093
Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775
E Mail:- finance@sfil.in, Website:- www.sfil.in, CIN :- L24239MH1988PLC047759

CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTERLY AND HALF YEARLY ENDED 30TH SEPTEMBER, 2026

Rs. In Lacs except EPS

S. No.	Particulars	Quarter Ended			Year to date ended		Year Ended
		30/09/2026	30/06/2026	30/09/2025	30/09/2026	30/09/2025	31/03/2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	*Audited
1	Revenue from Operations	14,214.49	12,552.64	12,171.74	26,767.13	23,861.91	48,917.15
2	Other Income	606.59	782.94	525.05	1,389.53	1,128.52	3,133.99
3	**Total Income (1 + 2)**	**14,821.08**	**13,335.58**	**12,696.79**	**28,156.66**	**24,990.43**	**52,051.14**
4	**EXPENSES**						
	(a) Cost of materials consumed	4,597.43	5,877.62	4,642.63	10,475.05	10,603.93	22,093.68
	(b) Purchases of Stock-in-Trade	1,748.00	1,824.49	1,529.13	3,572.49	3,097.26	6,722.87
	(c) Changes in inventories of finished goods, Stock-in- Trade and work-in-progress	1,034.69	(1,115.72)	903.71	(81.03)	291.23	(389.30)
	(d) Employee benefits expense	1,693.24	1,716.67	1,673.08	3,409.91	3,268.52	6,708.51
	(e) Finance costs	40.73	24.45	26.49	65.18	51.57	115.50
	(f) Depreciation and amortization expense	156.41	154.03	135.00	310.44	269.00	653.23
	(g) Other expenses	1,947.82	1,628.82	1,583.10	3,576.64	3,180.16	6,038.39
	Total expenses (4)	**11,218.32**	**10,110.36**	**10,493.14**	**21,328.68**	**20,761.67**	**41,942.88**
5	**Profit/(loss) before exceptional items and tax (3- 4)**	**3,602.77**	**3,225.22**	**2,203.65**	**6,827.99**	**4,228.76**	**10,108.26**
6	Exceptional Items	-	-	-	-	4.13	3.69
7	**Profit/(loss) before tax (5 - 6)**	**3,602.77**	**3,225.22**	**2,203.65**	**6,827.99**	**4,232.89**	**10,111.95**
8	Tax expense						
	(1) Current tax	911.42	727.65	513.90	1,639.07	946.40	2,286.73
	(2) Deferred tax	26.03	12.89	29.64	38.92	50.94	181.42
9	**Profit (Loss) for the period from continuing operations (7-8)**	**2,665.32**	**2,484.68**	**1,660.11**	**5,150.00**	**3,235.55**	**7,643.80**
10	Profit/(loss) from discontinued operations	-	-		-	-	-
11	Tax expense of discontinued operations	-	-		-	-	-
12	Profit/(loss) from Discontinued operations (after tax) (10-11)	-	-		-	-	-
13	**Profit/(loss) for the period (9 + 12)**	**2,665.32**	**2,484.68**	**1,660.11**	**5,150.00**	**3,235.55**	**7,643.80**
14	Other Comprehensive Income						
	A(*i*)Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(*ii*) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B (*i*) Items that will be reclassified to profit or loss	(46.95)	381.87	(5.58)	334.92	398.26	(360.73)
	(*ii*) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
15	**Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the period)**	**2,618.37**	**2,866.55**	**1,654.53**	**5,484.92**	**3,633.81**	**7,283.07**
16	Paid up Share Capital of the Company (Face Value 1/-)	9,400.00	9,400.00	9,400.00	9,400.00	9,400.00	9,400.00
17	Reserves excluding revaluation reserves			-		-	32,098.83
18	Earnings per equity share (for continuing operation):						
	(1) Basic	0.28	0.26	0.18	0.55	0.34	0.81
	(2) Diluted	0.28	0.26	0.18	0.55	0.34	0.81
19	Earnings per equity share (for discontinued operation):						
	(1) Basic	-	-	-	-	-	-
	(2) Diluted	-	-	-	-	-	-
20	Earnings per equity share (for discontinued & continuing operations)						
	(1) Basic	0.28	0.26	0.18	0.55	0.34	0.81
	(2) Diluted	0.28	0.26	0.18	0.55	0.34	0.81

Place: Indore
Date: 13/11/2026

For, Syncom Formulations (India) Limited

Ankit Kedarmal Bankda
Chairman & Wholetime Director
Din : 02359461

SYNCOM FORMULATIONS (INDIA) LIMITED

Regd.Off :- 7,Niraj Industrial Estate,Off Mahakali Caves Road,Andheri (E) Mumbai-400093
Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775
E Mail:- finance@sfil.in, Website:- www.sfil.in, CIN :- L24239MH1988PLC047759

CONSOLIDATED STATEMENT OF SEGMENT WISE REVENUE, RESULTS ALONG WITH QUARTERLY AND HALF YEARLY UNAUDITED RESULTS

Rs. In Lacs except EPS

S. No.	Particulars	Quarter Ended			Year to date ended		Year to date Ended
		30/09/2026	30/06/2026	30/09/2025	30/09/2026	30/09/2025	31/03/2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	*Audited
1	**Segment Revenue**						
	a) Pharmaceuticals Drugs & Formulations	14679.11	13223.61	12597.98	27902.72	24,697.93	51,573.38
	b) Trading of Commodities	14.44	27.84	0.00	42.28	104.56	110.03
	c) Renting of Property	127.53	84.13	98.81	211.66	187.94	367.73
	Total Segment Revenue	**14,821.08**	**13,335.58**	**12,696.79**	**28,156.66**	**24,990.43**	**52,051.14**
	Less: Inter Segment Revenue						-
	Total Income	**14,821.08**	**13,335.58**	**12,696.79**	**28,156.66**	**24,990.43**	**52,051.14**
2	**Segment Results Profit(+)/Loss(-) before tax and interest from each segment**						
	a) Pharmaceuticals Drugs & Formulations	3517.63	3170.25	2131.33	6687.88	4,097.05	9,931.87
	b) Trading of Commodities	7.49	1.99	0.00	9.48	1.35	(2.63)
	c) Renting of Property	118.38	77.43	98.81	195.81	181.93	298.21
	Total Profit before tax and Interest	**3,643.50**	**3,249.67**	**2,230.14**	**6,893.17**	**4,280.33**	**10,227.45**
	Less: i) Interest	40.73	24.45	26.49	65.18	51.57	115.50
	ii) Other Un-allocable Expenditure						-
	Profit before tax	**3,602.77**	**3,225.22**	**2,203.65**	**6,827.99**	**4,228.76**	**10,111.95**
3	**(Segment Asset-Segment Liabilities)**						
	Segment Asset						
	a) Pharmaceuticals Drugs & Formulations	48067.45	46037.15	40623.55	48067.45	40,623.55	43,976.01
	b) Trading of Commodities	0.29	4.56	251.35	0.29	251.35	66.51
	c) Renting of Property	9254.62	9257.24	4733.44	9254.62	4,733.44	9,342.00
	Total Segment Asset	**57,322.36**	**55,298.95**	**45,608.34**	**57,322.36**	**45,608.34**	**53,384.52**
	Un-allocable Assets	-	-	-	-	-	-
	Net Segment Asset	**57,322.36**	**55,298.95**	**45,608.34**	**57,322.36**	**45,608.34**	**53,384.52**
	Segment Liabilities						
	a) Pharmaceuticals Drugs & Formulations	10051.45	10789.14	7623.26	10051.45	7,623.26	11,713.50
	b) Trading of Commodities	3.09	12.50	2.11	3.09	2.11	4.12
	c) Renting of Property	284.07	284.16	133.40	284.07	133.40	168.07
	Total Segment Liabilities	**10,338.61**	**11,085.80**	**7,758.77**	**10,338.61**	**7,758.77**	**11,885.69**
	Un-allocable Liabilities	-	-	-	-	-	-
	Net Segment Liabilities	**10,338.61**	**11,085.80**	**7,758.77**	**10,338.61**	**7,758.77**	**11,885.69**

Notes:-

1. The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 13/11/2026
2. These above results have been prepared in compliance with the Indian Accounting Standard (referred to as "Ind AS") as notified prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules 2015 as amended from time to time.
3. The company is operating in 3 segments i.e. (a) Pharmaceuticals Drugs & Formulations (b) Trading of Commodities (c) Renting of Property, particulars of segment wise results are given as required.
4. As required under Regulation 33 of SEBI (LODR) Regulations, 2015 the limited review by the Statutory Auditors have been completed for the quarter and half year ended on 30th September, 2026. The report does not have any impact on the above results and notes which needs explanation.
5. Previous period figures have been regrouped/reclassified wherever necessary to confirm to this period classification.
6. The Company currently have 3 (three) Wholly Owned Subsidiaries namely Synmex Pharma Pvt. Ltd., Sante Biotech Pvt. Ltd. And Vincit Biotech International Pvt. Ltd.
7. The Standalone Statement of Assets and Liabilities as at 30th September, 2026 and the Standalone Statement of Cash Flow is provided as an annexure to this statement.
8. During the current period, the Company has corrected its method of calculating Earnings Per Share (EPS). In previous years/Quarters, EPS was calculated considering Total Comprehensive Income. To comply with the requirements of Ind AS 33, the EPS has now been computed using Profit After Tax attributable to equity shareholders. Consequently, the comparative EPS for all preceding periods has been restated. There is no restatement in any line items only EPS is restated. The Figurs as Previously reported and restated are as below

Previously Reported EPS (TCI)	Quarter Ended			Year Ended		Year Ended
	30/09/2026	30/06/2026	30/09/2025	30/09/2026	30/09/2025	31/03/2026
	Audited	Unaudited	Audited	Audited	Audited	Audited
Earnings per equity share (for discontinued & continuing operations)						
(1) Basic	NA	NA	0.18	NA	0.39	NA
(2) Diluted	NA	NA	0.18	NA	0.39	NA
Restated EPS (PAT))						
Earnings per equity share (for discontinued & continuing operations)						
(1) Basic	0.28	0.26	0.18	0.55	0.34	0.81
(2) Diluted	0.28	0.26	0.18	0.55	0.34	0.81

Place: Indore
Date: 13/11/2026

For, Syncom Formulations (India) Limited

Ankit Kedarmal Bankda
Chairman & Wholetime Director
Din : 02359461

SYNCOM FORMULATIONS (INDIA) LIMITED

Regd.Off :- 7,Niraj Industrial Estate,Off Mahakali Caves Road,Andheri (E) Mumbai-400093
Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775
E Mail:- finance@sfil.in, Website:- www.sfil.in, CIN :- L24239MH1988PLC047759

CONSOLIDATED Statement of Assets & Liabilities as at 30/09/2026

Particulars Rs. In Lacs	30/09/2026 Un-Audited	31/03/2026 *Audited
ASSETS		
Non-current assets		
(a) Property, Plant and Equipment	8,871.88	8,976.66
(b) Capital Work in Progress	361.77	
(c) Intangible assets	38.08	39.72
(d) Investment Property	9,253.92	9,334.67
(e) Financial Assets		
(i) Investments	259.58	253.43
(ii) Fixed Deposits & Accrued Interest	1,557.41	1,541.45
(iii) Deposits	75.75	70.90
(f) Other Non Current Assets	763.19	131.15
Current assets		
(a) Inventories	4,240.78	6,287.85
(b) Financial Assets		
(i) Investments	17,098.01	10,651.64
(ii) Trade Receivables	12,360.36	11,050.48
(iii) Cash And Cash Equivalents	33.65	514.75
(iv) Bank Balances other than (iii) above	122.92	119.12
(v) Deposits	396.74	381.48
(vi) Loans & Advances	770.45	703.93
(d) Other Current Assets	1,117.87	3,327.29
Total	**57,322.36**	**53,384.52**
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share Capital	9,400.00	9,400.00
(b) Other Equity	37,583.75	32,098.83
Liabilities		
Non Current Liabilities		
(a) Financial Liabilities		
(i) Trade and other Deposits	275.04	157.65
(b) Provisions	481.32	541.17
(c) Deferred Tax Liabilities (Net)	851.39	812.47
(d) Other Non Current Liabilities	1.91	1.82
Current liabilities		
(a) Financial liabilities		
(i) Borrowings	1,635.21	147.42
(ii) Trade Payables	-	-
Total Outstanding Dues of Micro Enterprises and Small Enterprises	728.74	586.78
Total Outstanding Dues of Creditors other than Micro Enterprises and Small Enterprises	3,764.66	6,852.24
(iii) Other Financial Liabilities	213.68	215.48
(b) Other Current Liabilities	1,189.72	1,928.58
(c) Provisions	1,196.94	642.08
Total	**57,322.36**	**53,384.52**

Place: Indore
Date: 13/11/2026

For, Syncom Formulations (India) Limited

Ankit Kedarmal Bankda
Chairman & Wholetime Director
Din : 02359461

SYNCOM FORMULATIONS (INDIA) LIMITED

Regd.Off :- 7,Niraj Industrial Estate,Off Mahakali Caves Road,Andheri (E) Mumbai-400093

Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775

E Mail:- finance@sfil.in, Website:- www.sfil.in, CIN :- L24239MH1988PLC047759

CONSOLIDATED Cash Flow Statement for the year ended 30/09/2026

Particulars Rs. In Lacs	30/09/2026 Un-Audited	31/03/2026 Audited
Cash Flow from Operating Activities		
Profit before extraordinary item and tax	6827.985	10,108.26
Adjustments for:		
Gain on Sale of Machinery / (Loss on Sale of Vehicle)	0	3.69
Gain/(Loss) on Actuarial valuation of employee benefits	-8.51	9.83
Depreciation	310.44	653.23
Depreciation Written Back	0	(745.29)
Finance Costs	65.18	115.50
Other Income	-1377.54	(3,057.72)
Operating Profit before working capital changes	**5,817.56**	**7,087.50**
Changes in Working Capital		
Inventory	2047.07	(2,154.65)
Trade Receivables	-1309.875	(295.63)
Loans & Advances	-66.52	(160.40)
Other Current Assets	2194.16	(1,136.43)
Trade Payables	-2945.62	3,025.85
Other Financial Liabilities	-1.71	4.30
Other Current Liabilities	-738.86	1,500.39
Short Term Provisions	554.86	223.73
Changes in Working Capital	(266.49)	1,007.16
Cash Generated from Operations before Tax	5551.06	8,094.66
Less: Income Tax Paid	1639.07	2,286.73
Net Cash From Operating Activities	**3,911.99**	**5,807.93**
Cash Flow from Investing Activities		
Change in Property Plant and Equipment, Intangible Assets and Capital Work in Progress	-565.79	(1,166.99)
Change in Investment Property	80.75	(4,601.23)
Change in Fixed Deposit & Accrued Interest	-19.76	(330.05)
Change in Deposits	-4.85	(4.28)
Change in Other Non Current Assets	-632.04	(49.57)
Change in Trade & Other Deposits	117.3942	24.30
Other Income	1377.54	3,057.72
Change in Investment	-6109.09	(1,992.17)
Net Cash from Investing Activities	**(5,755.85)**	**(5,062.27)**
Cash Flow from Financing Activities		
Finance Costs	-65.18	(115.50)
Change in Long Term Liabilities	-59.85	124.33
Issue of Warrants & Share capital	0	-
Dividend Paid	0	-
Borrowings	1487.79	(310.94)
Net Cash from Financing Activities	**1,362.76**	**(302.11)**
Net Decrease in Cash & Cash Equivalents	**(481.10)**	**443.55**
Cash & Cash Equivalents at the beginning of the Period	514.75	71.20
Cash & Cash Equivalents at the End of Period	**33.65**	**514.75**

Place: Indore
Date: 13/11/2026

For, Syncom Formulations (India) Limited

Ankit Kedarmal Bankda
Chairman & Wholetime Director
Din : 02359461